---
title: "BioMarin Pharmaceutical Q2 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294988557.md"
description: "BioMarin Pharmaceutical (BMRN) will report Q2 2026 earnings on August 6th after market close. Consensus estimates project EPS of $0.95, down 34% year-over-year, and revenue of $932.04 million, up 13% year-over-year. Historically, the company has beaten EPS estimates 63% of the time and revenue estimates 88% of the time over the past two years."
datetime: "2026-08-05T15:31:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294988557.md)
  - [en](https://longbridge.com/en/news/294988557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294988557.md)
generator: "portal-rs"
---

# BioMarin Pharmaceutical Q2 2026 earnings preview

BioMarin Pharmaceutical (BMRN) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is $0.95 (-34.0% Y/Y) and the consensus Revenue Estimate is $932.04M (+13.0% Y/Y). Over the last 2 years, BMRN has beaten EPS estimates 63% of the time and has beaten revenue estimates 88% of the time. ...

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)
- [Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN](https://longbridge.com/en/news/296092450.md)
- [BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment](https://longbridge.com/en/news/296376333.md)
- [Boehringer again rises up rare disease reputation rankings](https://longbridge.com/en/news/296577935.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**